{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:07:27Z","timestamp":1791986847313,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nitric Oxide"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.niox.2019.09.002","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T01:41:17Z","timestamp":1568684477000},"page":"44-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Interleukin enhancement binding factor 3 inhibits cardiac hypertrophy by targeting asymmetric dimethylarginine-nitric oxide"],"prefix":"10.1016","volume":"93","author":[{"given":"Ruo-Han","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian-Jie","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Cen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.niox.2019.09.002_bib1","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1161\/CIRCULATIONAHA.114.008788","article-title":"Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling","volume":"131","author":"Frieler","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.niox.2019.09.002_bib2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nrd3431","article-title":"Novel therapeutic targets for the treatment of heart failure","volume":"10","author":"Tamargo","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.niox.2019.09.002_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/CIRCIMAGING.117.007451","article-title":"Progression of hypertrophy and myocardial fibrosis in aortic stenosis: a multicenter cardiac magnetic resonance study","volume":"11","author":"Everett","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.niox.2019.09.002_bib4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrcardio.2011.172","article-title":"Reverse remodeling in heart failure--mechanisms and therapeutic opportunities","volume":"9","author":"Koitabashi","year":"2011","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.niox.2019.09.002_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1172\/JCI62839","article-title":"Signaling effectors underlying pathologic growth and remodeling of the heart","volume":"123","author":"van Berlo","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.niox.2019.09.002_bib6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1161\/CIRCRESAHA.112.279760","article-title":"Increased oxidative stress in the nucleus caused by Nox4 mediates oxidation of HDAC4 and cardiac hypertrophy","volume":"112","author":"Matsushima","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.niox.2019.09.002_bib7","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1089\/ars.2014.5983","article-title":"The role of SUMO-1 in cardiac oxidative stress and hypertrophy","volume":"21","author":"Lee","year":"2014","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.niox.2019.09.002_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.7888\/juoeh.35.147","article-title":"Nitric oxide synthases and heart failure - lessons from genetically manipulated mice","volume":"35","author":"Shibata","year":"2013","journal-title":"J. UOEH"},{"key":"10.1016\/j.niox.2019.09.002_bib9","first-page":"533","article-title":"The m(6)A mRNA methylase METTL3 controls cardiac homeostasis and hypertrophy","author":"Dorn","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.niox.2019.09.002_bib10","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2017.07.789","article-title":"Bone marrow-derived tenascin-C attenuates cardiac hypertrophy by controlling inflammation","volume":"70","author":"Song","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.niox.2019.09.002_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.004953","article-title":"Increased cardiac uptake of ketone bodies and free fatty acids in human heart failure and hypertrophic left ventricular remodeling","volume":"11","author":"Voros","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.niox.2019.09.002_bib12","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/01.RES.85.7.575","article-title":"Heterogeneous basal expression of nitric oxide synthase and superoxide dismutase isoforms in mammalian heart : implications for mechanisms governing indirect and direct nitric oxide-related effects","volume":"85","author":"Brahmajothi","year":"1999","journal-title":"Circ. Res."},{"key":"10.1016\/j.niox.2019.09.002_bib13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1742-7843.2008.00261.x","article-title":"L-arginine inhibits isoproterenol-induced cardiac hypertrophy through nitric oxide and polyamine pathways","volume":"103","author":"Lin","year":"2008","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.niox.2019.09.002_bib14","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1253\/circj.66.851","article-title":"Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion","volume":"66","author":"Ozaki","year":"2002","journal-title":"Circ. J."},{"key":"10.1016\/j.niox.2019.09.002_bib15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000370025","article-title":"Nitric oxide synthase inhibition abolishes exercise-mediated protection against isoproterenol-induced cardiac hypertrophy in female mice","volume":"130","author":"Ren","year":"2015","journal-title":"Cardiology"},{"key":"10.1016\/j.niox.2019.09.002_bib16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/MCA.0b013e328323982f","article-title":"Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography","volume":"20","author":"Cavusoglu","year":"2009","journal-title":"Coron. Artery Dis."},{"key":"10.1016\/j.niox.2019.09.002_bib17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1523-1755.2002.00437.x","article-title":"Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients","volume":"62","author":"Zoccali","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.niox.2019.09.002_bib18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/wrna.1270","article-title":"Ilf3 and NF90 functions in RNA biology","volume":"6","author":"Castella","year":"2015","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"10.1016\/j.niox.2019.09.002_bib19","doi-asserted-by":"crossref","first-page":"6249","DOI":"10.1093\/nar\/gkm668","article-title":"Novel rapidly evolving hominid RNAs bind nuclear factor 90 and display tissue-restricted distribution","volume":"35","author":"Parrott","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.niox.2019.09.002_bib20","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1096\/fj.04-1763fje","article-title":"Ilf3 and NF90 associate with the axonal targeting element of Tau mRNA","volume":"18","author":"Larcher","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.niox.2019.09.002_bib21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.atherosclerosis.2010.12.005","article-title":"Association of a polymorphism of BTN2A1 with myocardial infarction in East Asian populations","volume":"215","author":"Yamada","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.niox.2019.09.002_bib22","first-page":"3304","article-title":"RNA stability protein ILF3 mediates cytokine-induced angiogenesis","author":"Vrakas","year":"2018","journal-title":"FASEB J."},{"key":"10.1016\/j.niox.2019.09.002_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135498","article-title":"Elevated levels of asymmetric dimethylarginine (ADMA) in the pericardial fluid of cardiac patients correlate with cardiac hypertrophy","volume":"10","author":"Nemeth","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.niox.2019.09.002_bib24","doi-asserted-by":"crossref","first-page":"19866","DOI":"10.1074\/jbc.M000023200","article-title":"Protein-arginine methyltransferase I, the predominant protein-arginine methyltransferase in cells, interacts with and is regulated by interleukin enhancer-binding factor 3","volume":"275","author":"Tang","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.niox.2019.09.002_bib25","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1016\/j.bmc.2016.08.009","article-title":"Understanding protein arginine methyltransferase 1 (PRMT1) product specificity from molecular dynamics","volume":"24","author":"Gathiaka","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.niox.2019.09.002_bib26","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1161\/HYPERTENSIONAHA.116.08662","article-title":"Crucial role of ROCK2-mediated phosphorylation and upregulation of FHOD3 in the pathogenesis of angiotensin II-induced cardiac hypertrophy","volume":"69","author":"Zhou","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.niox.2019.09.002_bib27","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/cns.12679","article-title":"The phosphoinositide-3 kinase signaling is involved in neuroinflammation in hypertensive rats","volume":"23","author":"Tan","year":"2017","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.niox.2019.09.002_bib28","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/HJH.0000000000000887","article-title":"Centrally acting drug moxonidine decreases reactive oxygen species via inactivation of the phosphoinositide-3 kinase signaling in the rostral ventrolateral medulla in hypertensive rats","volume":"34","author":"Wang","year":"2016","journal-title":"J. Hypertens."},{"key":"10.1016\/j.niox.2019.09.002_bib29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.niox.2017.04.002","article-title":"The asymmetric dimethylarginine-mediated inhibition of nitric oxide in the rostral ventrolateral medulla contributes to regulation of blood pressure in hypertensive rats","volume":"67","author":"Tan","year":"2017","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.niox.2019.09.002_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4103\/1008-682X.178486","article-title":"Epigallocatechin-3-gallate ameliorates erectile function in aged rats via regulation of PRMT1\/DDAH\/ADMA\/NOS metabolism pathway","volume":"19","author":"Chen","year":"2017","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.niox.2019.09.002_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.115.002680","article-title":"Angiotensin-Converting enzyme 3 (ACE3) protects against pressure overload-induced cardiac hypertrophy","volume":"5","author":"Yu","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.niox.2019.09.002_bib32","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.bbrc.2016.11.090","article-title":"G protein coupled receptor kinase-2 upregulation causes kappa-opioid receptor desensitization in diabetic heart","volume":"482","author":"Chen","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.niox.2019.09.002_bib33","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/aps.2010.73","article-title":"Activation of AMPK inhibits cardiomyocyte hypertrophy by modulating of the FOXO1\/MuRF1 signaling pathway in vitro","volume":"31","author":"Chen","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"issue":"Suppl N","key":"10.1016\/j.niox.2019.09.002_bib34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/eurheartj\/16.suppl_N.8","article-title":"The biological cascade leading to cardiac hypertrophy","volume":"16","author":"Neyses","year":"1995","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.niox.2019.09.002_bib35","first-page":"1389","article-title":"SIRT4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity","volume":"38","author":"Luo","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.niox.2019.09.002_bib36","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCRESAHA.110.232306","article-title":"Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure","volume":"108","author":"Dai","year":"2011","journal-title":"Circ. Res."},{"key":"10.1016\/j.niox.2019.09.002_bib37","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/eurheartj\/ehy085","article-title":"CXCL1-CXCR2 axis mediates angiotensin II-induced cardiac hypertrophy and remodelling through regulation of monocyte infiltration","volume":"39","author":"Wang","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.niox.2019.09.002_bib38","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1161\/ATVBAHA.115.305230","article-title":"Histone methyltransferase SET1 mediates angiotensin II-induced endothelin-1 transcription and cardiac hypertrophy in mice","volume":"35","author":"Yu","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.niox.2019.09.002_bib39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00395-015-0477-6","article-title":"ROS and endothelial nitric oxide synthase (eNOS)-dependent trafficking of angiotensin II type 2 receptor begets neuronal NOS in cardiac myocytes","volume":"110","author":"Jang","year":"2015","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.niox.2019.09.002_bib40","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/bies.20049","article-title":"Nitric oxide and the enigma of cardiac hypertrophy","volume":"26","author":"Kempf","year":"2004","journal-title":"Bioessays"},{"key":"10.1016\/j.niox.2019.09.002_bib41","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1097\/HJH.0b013e32834bbb4d","article-title":"Role of angiotensin-converting enzyme 2 in cardiac hypertrophy induced by nitric oxide synthase inhibition","volume":"29","author":"Inaba","year":"2011","journal-title":"J. Hypertens."},{"key":"10.1016\/j.niox.2019.09.002_bib42","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1161\/CIRCULATIONAHA.107.737031","article-title":"Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy","volume":"117","author":"Moens","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.niox.2019.09.002_bib43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4161\/cc.27353","article-title":"Protein arginine methylation of non-histone proteins and its role in diseases","volume":"13","author":"Wei","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.niox.2019.09.002_bib44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.niox.2018.06.004","article-title":"Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease","volume":"78","author":"Liu","year":"2018","journal-title":"Nitric Oxide"},{"issue":"Suppl 2","key":"10.1016\/j.niox.2019.09.002_bib45","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/j.diabres.2008.09.024","article-title":"ADMA, cardiovascular disease and diabetes","volume":"82","author":"Krzyzanowska","year":"2008","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.niox.2019.09.002_bib46","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1042\/BJ20101793","article-title":"Interleukin enhancer-binding factor 3 functions as a liver receptor homologue-1 co-activator in synergy with the nuclear receptor co-activators PRMT1 and PGC-1alpha","volume":"437","author":"Ohno","year":"2011","journal-title":"Biochem. J."},{"key":"10.1016\/j.niox.2019.09.002_bib47","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4161\/cc.27353","article-title":"Protein arginine methylation of non-histone proteins and its role in diseases","volume":"13","author":"Wei","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.niox.2019.09.002_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-017-0644-z","article-title":"Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction","volume":"112","author":"Xu","year":"2017","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.niox.2019.09.002_bib49","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.niox.2018.06.004","article-title":"Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease","volume":"78","author":"Liu","year":"2018","journal-title":"Nitric Oxide"}],"container-title":["Nitric Oxide"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089860319300394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089860319300394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:05:06Z","timestamp":1761069906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089860319300394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":49,"alternative-id":["S1089860319300394"],"URL":"https:\/\/doi.org\/10.1016\/j.niox.2019.09.002","relation":{},"ISSN":["1089-8603"],"issn-type":[{"value":"1089-8603","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin enhancement binding factor 3 inhibits cardiac hypertrophy by targeting asymmetric dimethylarginine-nitric oxide","name":"articletitle","label":"Article Title"},{"value":"Nitric Oxide","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.niox.2019.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}